Trials / Completed
CompletedNCT06603623
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 647 (actual)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-2100 | BHV-2100 75mg |
| DRUG | BHV-2100 | BHV-2100 150 mg |
| DRUG | Placebo | matching placebo |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2025-03-24
- Completion
- 2025-03-28
- First posted
- 2024-09-19
- Last updated
- 2026-02-25
Locations
60 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06603623. Inclusion in this directory is not an endorsement.